cogitum-instruction

AUTHENTIC PRODUCTS

Only original pharmaceutical products that passed 3 stages of clinical trials.

GMP QUALITY

Our products are produced on GMP or state licensed factories.

10% CRYPTO DISCOUNT

10% discount for paying in BTC or other cryptocurrency.

PAYMENT BY CARD

Convenient Payment by Visa or MasterCard.

GUARANTEED DELIVERY

Guaranteed delivery times and clear Reshipment & Refund Rules.

PROMPT SHIPPING

Different shipping methods and same or next day shipping.

COGITUM ®

0 Reviews

Legal Disclaimer

All statements on this page are for informational purposes only and have not been evaluated by the US FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. Before using this product consulting a qualified MD is mandatory. See more

Buy more, get it as low as

2
$256.50
Save 5%
3
$251.10
Save 7%
4
$245.70
Save 9%
5
$240.30
Save 11%
6
$237.60
Save 12%
7
$234.90
Save 13%
8
$232.20
Save 14%
9 +
$229.50
Save 15%
Show More

Cogitum is an adaptogen with tonic and stimulating properties. It has a 40-year-long track record of successful application.

Cogitum is widely used in pediatrics and child neurology for treating delayed development, asthenic syndrome and for increasing endurance and mental performance in children and adolescents during high loads. The drug is prescribed in children aged 7 years and older. It enhances memory due to D-Aspartic acid which is a well-known metabolite. Cogitum is well tolerated in children and has a significant effect. However, it does not provide for an immediate effect as the child’s mental state improves gradually.

Cogitum is also a good option for adults in case of asthenia, heavy workload, recovery from different diseases, or the need for an increase in mental performance.

Pharmacodynamic properties

The drug is based on N-Acetylaspartic acid, which is a biologically active compound contained in the central nervous system (CNS). The drug stabilizes nervous regulation and has a stimulating effect.

Indications

  • As part of complex therapy of asthenic syndrome;
  • Fatigue with/without low mood;
  • As an adjuvant for antidepressants;
  • In pediatrics, Cogitum can be used as part of complex therapy of intellectual disability, birth defects of the central nervous system, delayed mental and speech development, delay in motor skills development, etc.

 

Produced by Sanofi, France.

 

Buy Cogitum medication at Cosmic Nootropic! 

 


Legal Disclaimer
This product has not been approved by the US FDA. All statements on this page are for informational purposes only and have not been evaluated by the US FDA.
This product is not intended to diagnose, treat, cure, or prevent any disease. See more

Contents

30 ampoules per pack, 10 ml.

Active ingredient: N-Acetylaspartic acid 250 mg;
Inactive ingredients: Fructose 1,000 mg, methylparaben 15 mg, banana flavoring 7 mg, purified water up to 10 ml.

Dosage and administration

Oral administration. The dosage is to be determined by the doctor.

The average dose for adults is 3 ampules per day: 2 in the morning and 1 before sleep. Dosage for children aged 7 to 10 is 1 ampule in the morning. Dosage for children aged 10 to 18 is 2 ampules in the morning.

Side effects

Allergic response.

Storage conditions

Keep out of the reach of children. Store in a dark place at a temperature not higher than 25°C.
Shelf life is 3 years.

Manufacturer

Sanofi, France.

  1. A Soulairac (1966) Examination of posture regulation by statokinesimetry. Its application to the study of vigilance levels in the normal subject before and after treatment with PC 63-14 https://www.ncbi.nlm.nih.gov/pubmed/4384261
  2. M Lambert (1967) Alcoholic disintoxication therapy and psychiatry. The place of PC 63-14 (cogitum) https://www.ncbi.nlm.nih.gov/pubmed/5613040
  3. J Guyotat (1968) Clinical trial in hospital setting of PC-63 14 (Cogitum). 30 cases https://www.ncbi.nlm.nih.gov/pubmed/4391394
  4. A Soulairac, N Aymard (1968) Neuropsychic disorders due to alcoholism: clinical and biologic results of their treatment by PC 63-14 (dipotassium acetyl-amino-succinate) https://www.ncbi.nlm.nih.gov/pubmed/4392390
  5. M Portmann, G Lacher (1968) Various reflections apropos of the use of PC 63-14 in reception deafness https://www.ncbi.nlm.nih.gov/pubmed/4388110
  6. P Orsini (1969) Acoustic trauma. Therapeutic trial of PC 63-14 (cogitum) https://www.ncbi.nlm.nih.gov/pubmed/4388850
  7. C Bouvier, A Masquin (1969) Therapeutic effects of PC 63-14 in psychiatric practice https://www.ncbi.nlm.nih.gov/pubmed/5363736
  8. Dubovtseva et al (1999) New approaches in the treatment of speech disorders in children with an organic brain lesion https://www.ncbi.nlm.nih.gov/pubmed/4388850
  9. O Milovanova, S Astanina (2016) Treatment of asthenoneurotic disorders in children https://www.ncbi.nlm.nih.gov/pubmed/28139636

0

Based on 0 Reviews

(0)

(0)

(0)

(0)

(0)

 

Thank you!

You will now receive regular updates from us!